WO2025133872 - METHOD FOR REDUCING OXIDATION LEVELS IN VEDOLIZUMAB DURING CELL CULTURE PROCESS
National phase entry is expected:
Publication Number
WO/2025/133872
Publication Date
26.06.2025
International Application No.
PCT/IB2024/062690
International Filing Date
16.12.2024
Title **
[English]
METHOD FOR REDUCING OXIDATION LEVELS IN VEDOLIZUMAB DURING CELL CULTURE PROCESS
[French]
PROCÉDÉ DE RÉDUCTION DES NIVEAUX D'OXYDATION DANS LE VÉDOLIZUMAB PENDANT UN PROCESSUS DE CULTURE CELLULAIRE
Applicants **
INTAS PHARMACEUTICALS LTD.
Inventors
MAHALINGAM, Velu
SHAH, Kinchit
PATEL, Hiral S.
PANCHAXARI, Chitti
ADHIKARY, Laxmi
Priority Data
202321086787
19.12.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1954 | |
| EPO | Filing, Examination, Granting | 11587 | |
| Japan | Filing, Examination, Granting | 1960 | |
| South Korea | Filing, Examination, Granting | 1654 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,895
Contact Us
Abstract[English]
The present invention provides a method of producing Vedolizumab, comprising supplementing cell culture with Methionine and thereby reducing the oxidation of cell culture.[French]
La présente invention concerne un procédé de production de védolizumab, comprenant la supplémentation d'une culture cellulaire avec de la méthionine et ainsi la réduction de l'oxydation de la culture cellulaire.